Lambda Light Chain Multiple Myeloma in a Patient with Primary Biliary Cholangitis: Association or Mere Coincidence?

[1]  S. Rajkumar,et al.  Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management , 2020, American journal of hematology.

[2]  M. Manns,et al.  The future of autoimmune liver diseases – Understanding pathogenesis and improving morbidity and mortality , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[3]  E. W. Holt,et al.  Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches , 2020, Journal of clinical and translational hepatology.

[4]  Alexandra G. Smith,et al.  The impact of rheumatological disorders on lymphomas and myeloma: a report on risk and survival from the UK’s population-based Haematological Malignancy Research Network , 2019, Cancer epidemiology.

[5]  D. Dingli,et al.  Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma , 2018, Blood Cancer Journal.

[6]  S. Giralt,et al.  Autoimmune Disorders and Multiple Myeloma- Two Illustrative Case Reports and a Literature Review , 2018 .

[7]  Zhanguo Li,et al.  Monoclonal gammopathy in rheumatic diseases , 2018, Clinical Rheumatology.

[8]  K. Hemminki,et al.  Familial associations of lymphoma and myeloma with autoimmune diseases , 2017, Blood Cancer Journal.

[9]  M. Björkholm,et al.  History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study , 2016, Annals of Hematology.

[10]  R. Erasmus,et al.  Serum protein electrophoresis patterns in human immunodeficiency virus-infected individuals not on antiretroviral treatment , 2015, Annals of clinical biochemistry.

[11]  L. Murray,et al.  Prior Autoimmune Disease and Risk of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Systematic Review , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[12]  L. Brown,et al.  Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. , 2008, Blood.

[13]  G. Ozturk,et al.  Primary biliary cirrhosis and IgG-kappa type multiple myeloma both respond well to vincristine, adriamycin and dexamethasone: is there a pathogenic relationship? , 2008, Journal of the Formosan Medical Association = Taiwan yi zhi.

[14]  S. Walsh,et al.  Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States. , 2000, American journal of public health.

[15]  H. Adami,et al.  Cancer risk in primary biliary cirrhosis: A population‐based study from Sweden , 1994, Hepatology.

[16]  H. Hayakawa,et al.  Primary biliary cirrhosis associated with multiple myeloma. , 1993, Internal medicine.

[17]  M. Abe,et al.  Multiple myeloma occurring in early stage primary biliary cirrhosis. , 1993, The Tohoku journal of experimental medicine.

[18]  T. Oda,et al.  Primary biliary cirrhosis complicated with Sjögren syndrome and multiple myeloma. A case report. , 1996, Nephron.